Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Stoter

Showing results (21-30 of 249) with videos related to

Pageof 25
Sort By:
Cancer Treatment Reviews|September 28, 2000
Farnesyl transferase inhibitors: current developments and future perspectivesF A Eskens, G Stoter, J Verweij
Nederlands Tijdschrift Voor Geneeskunde|March 2, 1991
[Magnetic resonance spectroscopy; current possibilities for the staging of tumors and the evaluation of response to therapy]P E Sijens, G Stoter, M Oudkerk
Cancer Treatment Reviews|September 1, 1995
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effectsL C Pronk, G Stoter, J Verweij
Cancer|January 1, 1993
Stenting in malignant vena caval obstructionM Oudkerk, F M Heystraten, G Stoter
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1996
Immunotherapy of metastatic renal cell cancerS H Goey, J Verweij, G Stoter
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001
Interferon-alpha induced Raynaud's syndromeW H Kruit, A M Eggermont, G Stoter
Lancet (London, England)|February 20, 1988
Rapid alkalinisation for flavone acetic acid administration: a potentially hazardous procedureJ Verweij, G Stoter, P Dodion, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1989
Characteristics and uses of IL-2 in immunotherapyR L Bolhuis, G Stoter, A M Eggermont
Cancer Immunology, Immunotherapy : CII|September 4, 1999
The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cellsW H Kruit, P I Schmitz, G Stoter
American Journal of Clinical Oncology|April 1, 1993
Piritrexim-induced pulmonary toxicityR de Wit, J Verweij, R Slingerland, et al.
Pageof 25

Showing results (21-30 of 249) with videos related to

Sort By:
Pageof 25
Cancer Treatment Reviews|September 28, 2000
Farnesyl transferase inhibitors: current developments and future perspectivesF A Eskens, G Stoter, J Verweij
Nederlands Tijdschrift Voor Geneeskunde|March 2, 1991
[Magnetic resonance spectroscopy; current possibilities for the staging of tumors and the evaluation of response to therapy]P E Sijens, G Stoter, M Oudkerk
Cancer Treatment Reviews|September 1, 1995
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effectsL C Pronk, G Stoter, J Verweij
Cancer|January 1, 1993
Stenting in malignant vena caval obstructionM Oudkerk, F M Heystraten, G Stoter
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1996
Immunotherapy of metastatic renal cell cancerS H Goey, J Verweij, G Stoter
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001
Interferon-alpha induced Raynaud's syndromeW H Kruit, A M Eggermont, G Stoter
Lancet (London, England)|February 20, 1988
Rapid alkalinisation for flavone acetic acid administration: a potentially hazardous procedureJ Verweij, G Stoter, P Dodion, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1989
Characteristics and uses of IL-2 in immunotherapyR L Bolhuis, G Stoter, A M Eggermont
Cancer Immunology, Immunotherapy : CII|September 4, 1999
The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cellsW H Kruit, P I Schmitz, G Stoter
American Journal of Clinical Oncology|April 1, 1993
Piritrexim-induced pulmonary toxicityR de Wit, J Verweij, R Slingerland, et al.
Pageof 25